Loss of RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers Resistance to Chemotherapy

RASSF2 is a novel pro-apoptotic effector of K-Ras that is frequently inactivated in a variety of primary tumors by promoter methylation. Inactivation of RASSF2 enhances K-Ras-mediated transformation and overexpression of RASSF2 suppresses tumor cell growth. In this study, we confirm that RASSF2 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Jennifer, Freeman, Jessica, Donninger, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368207/
https://www.ncbi.nlm.nih.gov/pubmed/22693671
http://dx.doi.org/10.1155/2012/705948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368207/
https://www.ncbi.nlm.nih.gov/pubmed/22693671
http://dx.doi.org/10.1155/2012/705948

Ejemplares similares